Approved HIV Drugs
Approved HIV Drugs
CROI 2013: Can People with Resistant HIV Omit NRTIs When Switching to a New Regimen? [VIDEO]
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
- Written by Liz Highleyman
Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least 2 active agents can reduce pill burden and side effects without compromising effectiveness, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
Atazanavir (Reyataz) Label Update Adds Kidney Warning, Drug Interactions
- Details
- Category: HIV Treatment
- Published on Tuesday, 12 February 2013 00:00
- Written by FDA
Product label information for the HIV protease inhibitor atazanavir (brand name Reyataz) was recently revised to include new warnings about cholelithiasis or gall bladder stones and interstitial nephritis (a type of kidney inflammation), as well as interactions with several other medications, including the hepatitis C virus protease inhibitor boceprevir (Victrelis).
HIV11: Complera Combo Pill as Effective as Atripla for First HIV Treatment, but Better Tolerability
- Details
- Category: HIV Treatment
- Published on Tuesday, 20 November 2012 00:00
- Written by Liz Highleyman
The Complera (rilpivirine/tenofovir/emtricitabine) single-tablet regimen suppressed HIV as well as the Atripla (efavirenz/tenofovir/emtricitabine) combination pill in treatment-naive people, but led to fewer adverse events -- in particular neuropsychiatric side effects associated with efavirenz, according to a report at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) last week in Glasgow. 
HIV11: Stribild Matches Efficacy and Tolerability of Atripla or Boosted Atazanavir at 96 Weeks
- Details
- Category: HIV Treatment
- Published on Tuesday, 27 November 2012 00:00
- Written by Liz Highleyman
The Stribild single-tablet-regimen -- formerly dubbed the Quad -- demonstrated "robust and durable" efficacy and continued to be well-tolerated through 96 weeks, according to findings from 2 studies presented at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this month in Glasgow. 
Raltegravir (Isentress) Can Cause Central Nervous System Side Effects for People with HIV
- Details
- Category: HIV Treatment
- Published on Tuesday, 30 October 2012 00:00
- Written by Liz Highleyman
The HIV integrase inhibitor raltegravir (brand name Isentress) is generally safe and well-tolerated, but it can cause central nervous system (CNS) symptoms such as insomnia, dizziness, and mood changes, especially when used with other drugs that raise its levels in the body, researchers reported in the October 1, 2012, advance online edition of AIDS. 
More Articles...
- IDWeek 2012: Simplified Protease Inhibitor Monotherapy Fails to Maintain HIV Suppression
- ICAAC 2012: Atazanavir Linked to Kidney Stones in People with HIV
- 1 in 5 People on Atripla Switch, Usually Due to Central Nervous System Side Effects
- ICAAC 2012: Simplified Abacavir/Atazanavir Combo Keeps HIV Suppressed, May Help Bones
Web Design and Development by